5MC Stock Overview
A biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Leap Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.25 |
| 52 Week High | US$4.54 |
| 52 Week Low | US$0.082 |
| Beta | -0.17 |
| 1 Month Change | 60.76% |
| 3 Month Change | -10.56% |
| 1 Year Change | -88.45% |
| 3 Year Change | -97.66% |
| 5 Year Change | -98.70% |
| Change since IPO | -99.62% |
Recent News & Updates
Recent updates
Shareholder Returns
| 5MC | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -14.2% | -0.8% | 0.5% |
| 1Y | -88.5% | -13.4% | 15.8% |
Return vs Industry: 5MC underperformed the German Biotechs industry which returned -13.4% over the past year.
Return vs Market: 5MC underperformed the German Market which returned 15.8% over the past year.
Price Volatility
| 5MC volatility | |
|---|---|
| 5MC Average Weekly Movement | 85.8% |
| Biotechs Industry Average Movement | 5.7% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in DE Market | 12.8% |
| 10% least volatile stocks in DE Market | 3.1% |
Stable Share Price: 5MC's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 5MC's weekly volatility has increased from 47% to 86% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 52 | Doug Onsi | www.leaptx.com |
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead clinical stage drug candidate includes DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in various ongoing clinical trials for treating esophagogastric and gynecologic cancers, and colorectal cancer. The company also develops FL-501, a monoclonal antibody that inhibits GDF-15 protein that is in preclinical trial.
Leap Therapeutics, Inc. Fundamentals Summary
| 5MC fundamental statistics | |
|---|---|
| Market cap | €13.41m |
| Earnings (TTM) | -€61.30m |
| Revenue (TTM) | n/a |
Is 5MC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 5MC income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$69.64m |
| Earnings | -US$69.64m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.69 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 5MC perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/23 02:29 |
| End of Day Share Price | 2025/05/23 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Leap Therapeutics, Inc. is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Swayampakula Ramakanth | H.C. Wainwright & Co. |
| Wangzhi Li | Ladenburg Thalmann & Company |
| Tyler Van Buren | Piper Sandler Companies |